Siga Technologies
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company based in New York, specializing in health security and infectious disease markets. Established in 1995, the company develops antiviral drugs targeting lethal pathogens, including variola virus, which causes smallpox. Its primary product, TPOXX, is an orally administered antiviral treatment specifically designed for human smallpox disease. SIGA is dedicated to creating modern biodefense countermeasures against high-priority viral threats, aiming to prevent and treat diseases such as Ebola, dengue, and Lassa fever. The company primarily generates revenue from the United States market.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
2 past transactions
Plexus Vaccine
Acquisition in 2003
Plexus Vaccine engages in the research, development, and design of vaccine products for human and veterinary markets.
Hypernix Technologies
Acquisition in 2000
Hypernix Technologies, Ltd. is an internet software company focused on developing innovative communication solutions. The company is working on a freeware product that facilitates multilateral, real-time communication among users accessing specific URLs on the web. In addition to this product, Hypernix has established a homepage and web portal aimed at creating virtual communities, offering chat and multimedia services. The company plans to fully develop its product, market and distribute it, and provide ongoing support. Furthermore, Hypernix intends to sell advertising space on its platform and website, offer franchises to other websites, and monetize collected data through sales to publishers and data buyers. The company is also engaged in various e-commerce activities and is committed to advancing additional internet projects related to its core offerings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.